Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerofe with Doxorubicin in Metastatic Ovarian and Triple Negative Breast Cancer
NCT03634150Phase 2Withdrawn
- Sponsor
- Immune System Key Ltd.
- Start
- Sep 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nerofe in Malignant ovarian neoplasm (OC), triple-negative breast cancer (TNBC), sponsored by Immune System Key Ltd.. Planned start Sep 2018; status: withdrawn.
02
Drugs
nerofe
03
Conditions
Malignant ovarian neoplasm (OC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03634150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634150.